Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Poor Response of Venetoclax/Azacitidine in Monocytic-like Acute Myeloid Leukemia Might be Associated with Genetic Patterns and Could be Improved By Addition of Homoharringtonine

Guopan Yu, Yishan Chen, Zhao Yin, Yu Zhang, Weihua Zhao, Guangyang Weng, Xin Du, Danian Nie, Ziwen Guo, Zhiqiang Sun, Hongyu Zhang, Dongjun Lin, Xinquan Liang, Pengcheng Shi, Xuejie Jiang, Dan Xu, Li Xuan, Baohong Ping, Qifa Liu

Blood (2024) 144 (Supplement 1): 1516.

https://doi.org/10.1182/blood-2024-201974

Published: 2024

Journal Articles

Type 2 Diabetes Leads to the Senescence of the Bone Marrow Microenvironment, and the Increase in DNA Damage Repair Function of AML Cells Mediates Anthracycline Resistance through Sasp

Yun Huang, Xuejie Jiang, Zhiquan Long

Blood (2024) 144 (Supplement 1): 4138.

https://doi.org/10.1182/blood-2024-204702

Published: 2024

Journal Articles

The Efficacy and Safety of Homoharringtonine Added to Venetoclax and Azacitidine in the Frontline Treatment of Newly Diagnosed Acute Myeloid Leukemia, a Multi-Center Exploratory Cohort Study

Guopan Yu, Zurong Yao, Zhao Yin, Yu Zhang, Weihua Zhao, Guangyang Weng, Ziwen Guo, Zhiqiang Sun, Pengcheng Shi, Xuejie Jiang, Dan Xu, Li Xuan, Qifa Liu

Blood (2024) 144 (Supplement 1): 4283.

https://doi.org/10.1182/blood-2024-206872

Published: 2024

Journal Articles

Azacitidine, Venetoclax Combined with Chidamide (ABC-14 Regimen) As an Induction Therapy for Newly Diagnosed AML: A Real-World Retrospective Analysis By the ABC-14 Collaboration Group

Blood (2024) 144 (Supplement 1): 6014.

https://doi.org/10.1182/blood-2024-210211

Published: 2024

Journal Articles

Homoharringtonine Enhances the Anti-Leukemia Effect of Venetoclax in Acute Myeloid Leukemia with t(8;21)(q22;q22) Via Regulation of c-Myc/Bim Axis

Guopan Yu, Zhao Yin, Zurong Yao, Xiaqi Nie, Hua Jin, Yu Zhang, Dan Xu, Xuejie Jiang, Baohong Ping

Blood (2023) 142 (Supplement 1): 6038.

https://doi.org/10.1182/blood-2023-182668

Published: 2023

Journal Articles

Maintenance Therapy with Chidamide Decreases the Relapse in Fusion Gene-Positive AML Patients with MRD-Positive or ELN-High Risk

Guopan Yu, Zhao Yin, Jixian Huang, Huiqing He, Xuejie Jiang, Hongsheng Zhou, Pengcheng Huang, Yu Zhang

Blood (2023) 142 (Supplement 1): 5862.

https://doi.org/10.1182/blood-2023-182621

Published: 2023

Journal Articles

The Efficacy and Safety of CLAG±Ida/Mito+Ven As Salvage Therapy of Relapsed/Refractory Acute Myeloid Leukemia

Guopan Yu, Zhao Yin, Yu Zhang, Xuejie Jiang, Xiaqi Nie, Zurong Yao, Dan Xu, Pengcheng Shi

Blood (2023) 142 (Supplement 1): 5909.

https://doi.org/10.1182/blood-2023-184772

Published: 2023

Journal Articles

ALDH3A2 Regulates Ferroptosis By Participating in Fatty Acid Synthesis and Finally Lead to Chemotherapy Resistance in Acute Myeloid Leukemia

Yun Huang, Xuejie Jiang, Ling Jiang, Yujiao Zhang, Fang Liu, Ping Yan, Baoyi Yuan, Quan Wu, Yu Zhao

Blood (2023) 142 (Supplement 1): 2935.

https://doi.org/10.1182/blood-2023-174357

Published: 2023

Journal Articles

Homoharringtonine Overcomes the Negative Impact of Genetic Patterns on Venetoclax Plus Azacitidine Regimen in Relapsed/Refractory Acute Myeloid Leukemia: A Multi-Center, Cohort Study

Guopan Yu, Yu Zhang, Hua Jin, Zhao Yin, Guangyang Weng, Sijian Yu, Na Xu, Xin Du, Dongjun Lin, Jie Xiao, Zhiqiang Sun, Hongyu Zhang, Xinquan Liang, Ziwen Guo, Weihua Zhao, Min Dai, Xuejie Jiang, Li Xuan, Pengcheng Shi

Blood (2023) 142 (Supplement 1): 4262.

https://doi.org/10.1182/blood-2023-182847

Published: 2023

Journal Articles

Treatment Response and Impact Factor of Venetoclax Based Regimens in the Frontline Treatment of Newly Diagnosed Unfit Acute Myeloid Leukemia in the Real World of China

Guopan Yu, Zhao Yin, Dan Xu, Xuejie Jiang, Jieyu Ye, Yu Zhang

Blood (2022) 140 (Supplement 1): 11740.

https://doi.org/10.1182/blood-2022-169333

Published: 2022

Journal Articles

Prospective Evaluation of Sorafenib Combined with Chemotherapy in Newly Diagnosed Adult Core-Binding Factor Acute Myeloid Leukemia: An Open-Label, Randomized Controlled, Multicenter Phase II Trial

Pengcheng Shi, Xi Jia, Naying Liao, Yin Changxin, Huan Li, Xuejie Jiang, Guopan Yu, Jieyu Ye, Hong Qu, Yu Zhan, Chunju Wen, Yu Zhang, Qifa Liu

Blood (2022) 140 (Supplement 1): 2005–2006.

https://doi.org/10.1182/blood-2022-156348

Published: 2022

Journal Articles

Comparision of the Clinical and Prognostic Characteristic in Adult and Pediatric AML1/ETO-Positive Acute Myeloid Leukemia

Guopan Yu, Jiaheng Zhou, Jinchan Zhou, Jiale Qiu, Zhao Yin, Changxin Yin, Dan Xu, Xuejie Jiang, MD, Qifa Liu, MD, Fanyi Meng

Blood (2018) 132 (Supplement 1): 5170.

https://doi.org/10.1182/blood-2018-99-116558

Published: 2018

Journal Articles

Influence of FLT3 -ITD Mutation and Length on the Treatment Response and Prognosis in Cytogenetically Normal AML Patients

Xuejie Jiang, MD, Changxin Yin, Junya Sun, Jiaying Cheng, Qiang Wang, Guopan Yu, Ling Jiang, Dan Xu, Xiaoli Liu, Ru Feng, MD, Qifa Liu, MD

Blood (2018) 132 (Supplement 1): 5245.

https://doi.org/10.1182/blood-2018-99-111063

Published: 2018

Journal Articles

Gene Mutation Profile and Risk Stratification in AML1-ETO-Positive Acute Myeloid Leukemia Based on Next-Generation Sequencing

Guopan Yu, Changxin Yin, Fuqun Wu, Ling Jiang, Zhongxin Zheng, Dan Xu, Jiaheng Zhou, Xuejie Jiang, MD, Qifa Liu, MD, Fanyi Meng

Blood (2018) 132 (Supplement 1): 5249.

https://doi.org/10.1182/blood-2018-99-113494

Published: 2018

Journal Articles

A New Multi-Factor Risk Score System Depending on Gene Mutation and Overexpression for Predicting the Outcome in AML1-ETO-Positive Acute Myeloid Leukemia

Guo-Pan Yu, MD, Changxin Yin, Fuqun Wu, Dan Xu, Zhongxin Zheng, Ling Jiang, PhD MD, Fang Chen, Xuejie Jiang, MD, Qifa Liu, Fanyi Meng

Blood (2017) 130 (Supplement 1): 5088.

https://doi.org/10.1182/blood.V130.Suppl_1.5088.5088

Published: 2017

Journal Articles

Influence of FLT3-ITD Mutation and Length on the Prognosis in Acute Myeloid Leukemia

Xuejie Jiang, MD, Fang Chen, Changxin Yin, Ling Jiang, PhD MD, Guo-Pan Yu, MD, Dan Xu, Jing Sun, MD, Xiaoli Liu, MD PhD, Qifa Liu

Blood (2017) 130 (Supplement 1): 5089.

https://doi.org/10.1182/blood.V130.Suppl_1.5089.5089

Published: 2017

Journal Articles

MiR-144 Targets APP to Regulate AML1/ETO+ Leukemia Cell Migration Via p-ERK/c-Myc/MMP-2 Pathway

Fanyi Meng, Ling Jiang, PhD MD, Wei Meng, PhD, Guo-Pan Yu, MD, Yin Changxin, Zhixiang Wang, PhD, Xuejie Jiang, MD, Qifa Liu

Blood (2017) 130 (Supplement 1): 5093.

https://doi.org/10.1182/blood.V130.Suppl_1.5093.5093

Published: 2017

Journal Articles

Berberine Acts As a Putative Epigenetic Modulator By Affecting Histone Code in Acute Myelocytic Leukemia Cells

Zhixiang Wang, PhD, Qifa Liu, Xuejie Jiang, MD, Yu Zhang, PhD, Ling Jiang, PhD MD, Fanyi Meng

Blood (2017) 130 (Supplement 1): 4989.

https://doi.org/10.1182/blood.V130.Suppl_1.4989.4989

Published: 2017

Journal Articles

Inhibition of FAK Exerts Anti-Leukemic Activity and Potentiates ABT-199-Induced Apoptosis in AML

Xiangmeng Wang, Po Yee Mak, MPhil, Hong Mu, MD PhD, Xuejie Jiang, Duncan Mak, BSc, MPhil, Jonathan A. Pachter, PhD, David T. Weaver, PhD, Bing Xu, PhD, Michael Andreeff, MD PhD, Bing Z Carter, PhD

Blood (2016) 128 (22): 1574.

https://doi.org/10.1182/blood.V128.22.1574.1574

Published: 2016

Journal Articles

BM-MSC Hhip Induced Microenvironment Protection from Chemotherapy in AML Via Ptch/Smo/Gli Pathwa

Xuejie Jiang, Dan Xu, Fang Chen, Ling Jiang, Guopan Yu, Fanyi Meng, Xiaoli Liu, PhD, Qifa Liu, MD

Blood (2016) 128 (22): 5235.

https://doi.org/10.1182/blood.V128.22.5235.5235

Published: 2016

NARROW

Poor Response of Venetoclax/Azacitidine in Monocytic-like Acute Myeloid Leukemia Might be Associated with Genetic Patterns and Could be Improved By Addition of Homoharringtonine

Type 2 Diabetes Leads to the Senescence of the Bone Marrow Microenvironment, and the Increase in DNA Damage Repair Function of AML Cells Mediates Anthracycline Resistance through Sasp

The Efficacy and Safety of Homoharringtonine Added to Venetoclax and Azacitidine in the Frontline Treatment of Newly Diagnosed Acute Myeloid Leukemia, a Multi-Center Exploratory Cohort Study

Azacitidine, Venetoclax Combined with Chidamide (ABC-14 Regimen) As an Induction Therapy for Newly Diagnosed AML: A Real-World Retrospective Analysis By the ABC-14 Collaboration Group

Homoharringtonine Enhances the Anti-Leukemia Effect of Venetoclax in Acute Myeloid Leukemia with t(8;21)(q22;q22) Via Regulation of c-Myc/Bim Axis

Maintenance Therapy with Chidamide Decreases the Relapse in Fusion Gene-Positive AML Patients with MRD-Positive or ELN-High Risk

The Efficacy and Safety of CLAG±Ida/Mito+Ven As Salvage Therapy of Relapsed/Refractory Acute Myeloid Leukemia

ALDH3A2 Regulates Ferroptosis By Participating in Fatty Acid Synthesis and Finally Lead to Chemotherapy Resistance in Acute Myeloid Leukemia

Homoharringtonine Overcomes the Negative Impact of Genetic Patterns on Venetoclax Plus Azacitidine Regimen in Relapsed/Refractory Acute Myeloid Leukemia: A Multi-Center, Cohort Study

Treatment Response and Impact Factor of Venetoclax Based Regimens in the Frontline Treatment of Newly Diagnosed Unfit Acute Myeloid Leukemia in the Real World of China

Prospective Evaluation of Sorafenib Combined with Chemotherapy in Newly Diagnosed Adult Core-Binding Factor Acute Myeloid Leukemia: An Open-Label, Randomized Controlled, Multicenter Phase II Trial

Comparision of the Clinical and Prognostic Characteristic in Adult and Pediatric AML1/ETO-Positive Acute Myeloid Leukemia

Influence of FLT3 -ITD Mutation and Length on the Treatment Response and Prognosis in Cytogenetically Normal AML Patients

Gene Mutation Profile and Risk Stratification in AML1-ETO-Positive Acute Myeloid Leukemia Based on Next-Generation Sequencing

A New Multi-Factor Risk Score System Depending on Gene Mutation and Overexpression for Predicting the Outcome in AML1-ETO-Positive Acute Myeloid Leukemia

Influence of FLT3-ITD Mutation and Length on the Prognosis in Acute Myeloid Leukemia

MiR-144 Targets APP to Regulate AML1/ETO+ Leukemia Cell Migration Via p-ERK/c-Myc/MMP-2 Pathway

Berberine Acts As a Putative Epigenetic Modulator By Affecting Histone Code in Acute Myelocytic Leukemia Cells

Inhibition of FAK Exerts Anti-Leukemic Activity and Potentiates ABT-199-Induced Apoptosis in AML

BM-MSC Hhip Induced Microenvironment Protection from Chemotherapy in AML Via Ptch/Smo/Gli Pathwa

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only